Anti-angiogenic agents targeting tumour vasculature have an established place in clinical practice and new data is constantly emerging. However, despite rapid clinical uptake, a very large number of questions regarding these agents remain unanswered.
Introduction
The regulatory approval of agents targeting tumour vasculature such as Bevacizumab and oral multi-receptor tyrosine kinase inhibitors which include VEGF (Vascular Endothelial Growth Factor) receptors as one of their targets, has changed clinical practice swiftly and significantly. One potential attraction of anticancer agents designed against specific target molecules would be the logical design of biomarker assays based on some biological aspect of that target. However, despite rapid clinical uptake, a very large number of questions regarding these agents remain unanswered.
The question marks start at the precise nature of the anti-tumour effect and differential efficacy in otherwise similar patients/tumours, mechanisms of synergy with cytotoxic agents, optimal dose and scheduling with other targeted agents through to pre-selection of patients most likely to benefit from treatment and, probably most importantly at this time, accurate and feasible ways of assessing response to drug beyond tumour reduction on conventional imaging.
Vascular Endothelial Growth factor (VEGF or VEGF-A) is a potent proangiogenic growth factor expressed by most cancer cells and some tumour stromal cells. It belongs to the platelet-derived growth factor family (PDGF) together with other dimeric glycoproteins such as VEGF-B, VEGF-C, VEGF-D, VEFG-E and placenta growth factor (PlGF) 1 .
The available anti-VEGF agents act through various mechanisms. The possible approaches to identify markers of response to anti-angiogenic treatment can be divided into four major groups: markers isolated and analysed from tumour tissue, blood -based markers, imaging based criteria for response and patient factors such as changes on blood pressure.
Tumour derived markers.
The obvious candidate when trying to define and predict the response to anti-VEGF treatments would be VEGF expression. VEGF is overexpressed in the majority of tumours 9,1 but it is also present in stromal cells and vascular endothelium (see figure   1 ) 9 This is a very new concept of assessment of response to anti-VEGF treatment which warrants further evaluation.
Blood-based markers
VEGF levels can also be measured in body fluids. Patients with large tumour burden and widespread metastatic disease have increased levels of circulating VEGF; 7 there is a negative association between VEGF expression and prognosis 18, 19 .
Unfortunately detection and precise measurement of VEGF may be inaccurate due to a number of factors. The immunoassays used to detect circulating VEGF usually use capture antibodies which only detect free VEGF. A significant amount of VEGF is bound to plasma proteins such as α 2 -macroglobulin. Some of the antibodies are only specific for single VEGF isoforms. VEGF can also be released from the platelets and leukocytes during blood sampling and handling [20] [21] [22] . Two main isoforms of VEGF that are detectable in circulation are VEGF 121 and VEGF 165 . Some of the available assays only detect VEGF 121 or only VEGF 165 whilst others measure the sum of both isoforms 22 . At present there is no evidence that any of the isoforms has any advantages over the other. The serum VEGF concentration increases with clotting duration and temperature 23 and the VEGF levels found in serum are to a large extent representative of VEGF released from platelets during clotting rather than a tumour secreted protein 20, 24 .
The difficulties associated with the exact measurement of circulating VEGF levels, lack of international validated approach defining the standard operating procedures for blood In pre-clinical models treatment with a targeted VEGFR-2 antibody caused a dose-dependent reduction in viable CEPs that paralleled its anti-tumour activity 38 . In human studies the data is accumulating and CECs are increasingly thought to reflect the disease status as well as response to antiangiogenic treatment. Metastatic breast cancer patients treated with bevacizumab and erlotinib show clear changes of CECs levels comparing to baseline, this is most pronounced in the first 3 weeks of treatment and appears to predict response to treatment 39 . A study of patients treated with letrozole and bevacizumab showed that CECs are a biomarker of progression as an increase in CECs at week 3 compared to week 0 predicted worse PFS (0.015) 40 .
Patients with hepatocellular carcinoma (HCC) who responded to treatment with
Bevacizumab showed a dramatic drop in CEC levels 41 . Similarly the CEC levels show a significant decrease in patients with metastatic renal cell cancer 42 , GIST malignancies and colorectal cancer 26, 37 . On the other hand patients with pancreatic cancer responding to bevacizumab showed no correlation with CEC levels 43 . Interestingly CEP levels appear to increase in response to treatment with anti-angiogenic agents 34, 42 . An analysis of 4 phase II studies by Duda et al 37 suggested that CEC and CEP kinetics depend on the type of antiangiogenic agent and therefore their biomarker value is deferential.
Sunitinib induced a sustained decrease in CEPs but not CECs in patients with HCC, bevacizumab caused increase in CEPs but not CECs in ovarian cancer, and cediranib did not significantly change neither CEPs nor CECs in glioblastoma patients 37 .
In summary CEC and CEPs are likely to be helpful in future studies but more extensive research is clearly required.
Imaging based biomarkers
An idea that new blood vessels developing within the tumours can be captured by imaging techniques has been around for a long time. The tumour supplying blood vessels are often dilated and tortuous with abnormal branching patterns, dead ends and lack of structure typical for other organs such as presence of arterioles, capillaries and venules. The permeability of the new blood vessels is also often much higher.
Microvessel density has been previously mentioned and can be assessed in biopsy One of the first human studies evaluating dynamic contrast-enhanced MRI (DCE-MRI) was a study reported by Morgan et al 46 .
The study looked at dose-related changes in the contrast-enhancement parameters in DCE-MRI as a biomarker of response to an oral VEGF receptor tyrosine kinase inhibitor in the context of phase I trial. The study showed a statistically significant relationship between reduction in contrast enhancement and disease response to the drug suggesting that this method needs further evaluation and could potentially be used as an anti-VEGF treatment biomarker of response. Other studies also confirmed relationship of disease response and contrast uptake but without a correlation to response rate (see figure 2 ). The results of the studies using DCE-MRI are certainly very encouraging but require validation and further studies are ongoing [47] [48] [49] . Although the initial data shows the feasibility of DCE-MRI based biomarkers, the complexity and demand on patient and staff as well as considerable expense do not seem to support its use as a practical biomarker used on aday-to-day basis.
Biomarkers based on patient related factors such as changes in blood pressure have been reported 28 there appears to be correlation with response to anti-angiogenic 13 agents however the changes are not reliable enough to be used in clinical practice as indicators of response.
Conclusion
The identification and validation of biomarkers indicating not only benefit of antiangiogenic therapy but capable of directly influencing clinical decisions on dosage and scheduling are urgently needed. It remains unclear as to the optimal biomarker for this purpose; most likely, the combination of data from tissue, blood and imaging will ultimately prove most useful. As well as response, biomarkers of resistance to antiangiogenic therapy also need to be considered. Resistance to primary therapy may be due to a number of factors including tumours switching to alternate pathways that are not targeted by that agent. Emerging data of elevated levels of SDF1 correlating with poor outcome in recurrent glioblastoma refractory to Bev, and elevated levels of IL-6 in hepatocellular carcinoma resistant to sunitib suggest specific alternate pathways exist, can be identified and characterised and themselves be targeted by other antiangiogenic agents.
